ArticleNature communications2024
A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity.EMBO molecular medicine · 2026Article
- A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses.Journal of virology · 2026Article
- Article
- Review
- A Humanized Anti-gD Broadly Neutralizing Antibody Confers Complete Post-Exposure Protection Against Pseudorabies Virus.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Structural Advances in Respiratory Syncytial Virus: Implications for Vaccine and Antiviral Development.Microorganisms · 2026Review
- ScRNA-Seq and BCR Analysis of Murine Immune Responses to Inactivated DHAV-1 as a Model Antigen.Viruses · 2026Article
- Whole-Genome Phylodynamic Analysis of Respiratory Syncytial Virus-Maryland, USA, 2018-2024.Viruses · 2026Article
- Potency Evaluation and Predictive Quality Control System Construction Strategy for Respiratory Syncytial Virus mRNA Vaccines.Vaccines · 2026Review
- Article
- Rational design 2.0: transitioning from static structural biology to computational prioritization and iterative vaccine optimization for RSV.Frontiers in immunology · 2026Review
- Respiratory syncytial virus (RSV) antibody and small-molecule drugs: current status of clinical translation and challenges.Frontiers in microbiology · 2026Review
- Determinants of success and failure of antibody-based strategies against respiratory viruses: insights from RSV and SARS-CoV-2.Frontiers in immunology · 2026Review
- A novel bispecific nanobody protects mice against RSV infection via intranasal administration.Journal of virology · 2025Article
- Discovery and molecular mechanism of potent neutralizing antibody from humanized mice with respiratory syncytial virus.PLoS pathogens · 2025Article
- Broad-spectrum vaccines against various and evolving viruses: from antigen design to nanoparticle delivery.Journal of virology · 2025Review
- The Yin and Yang of Antibodies in Viral Infectious Diseases.Diseases (Basel, Switzerland) · 2025Review
- Respiratory Syncytial Virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab Prophylaxis.Open forum infectious diseases · 2025Article
- Challenges and Limitations of Current RSV Prevention Strategies in Infants and Young Children: A Narrative Review.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) poses a significant public health challenge, especially among children. Although palivizumab and nirsevimab, neutralizing antibodies (nAbs) targeting the RSV F protein, have been used for prophylaxis, their limitations underscore the need for more effective alternatives. Herein, we present a potent and broad nAb, named 5B11, which exhibits nanogram level of unbiased neutralizing activities against both RSV-A and -B subgroups. Notably, 5B11 shows a ~20-fold increase in neutralizing efficacy compared to 1129 (the murine precursor of palivizumab) and approximately a 3-fold increase in neutralizing efficacy against B18537 in comparison to nirsevimab. Cryo-electron microscopy analysis reveals 5B11's mechanism of action by targeting a highly conserved epitope within site V, offering a promising strategy with potentially lower risk of escape mutants. Antiviral testing in a female cotton rat model demonstrated that low-dose (1.5 mg/kg) administration of 5B11 achieved comparable prophylactic efficacy to that achieved by high-dose (15 mg/kg) of 1129. Furthermore, the humanized 5B11 showed a superior in vivo antiviral activity against B18537 infection compared to nirsevimab and palivizumab. Therefore, 5B11 is a promising RSV prophylactic candidate applicable to broad prevention of RSV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.